NCT01007370

Brief Summary

The investigators aim to compare two different types of supraglottic devices for tracheal intubation in patients undergoing elective surgery under general anesthesia. Our hypothesis is that the use of the I-gel supraglottic airway will result in a higher first attempt success rate of blind tracheal intubation.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
160

participants targeted

Target at P75+ for not_applicable

Timeline
Completed

Started Mar 2010

Shorter than P25 for not_applicable

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

November 3, 2009

Completed
1 day until next milestone

First Posted

Study publicly available on registry

November 4, 2009

Completed
4 months until next milestone

Study Start

First participant enrolled

March 1, 2010

Completed
2 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

May 1, 2010

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

May 1, 2010

Completed
Last Updated

August 3, 2017

Status Verified

August 1, 2017

Enrollment Period

2 months

First QC Date

November 3, 2009

Last Update Submit

August 2, 2017

Conditions

Keywords

tracheal intubationsupraglottic airway devices

Outcome Measures

Primary Outcomes (1)

  • First attempt success rate of tracheal intubation.

    After successful insertion of tracheal tube

Secondary Outcomes (4)

  • Time needed for successful insertion of a supraglottic device.

    After insertion

  • First and total attempt success rate of supraglottic device insertion.

    After insertion

  • Total time and number of attempts needed to obtain successful tracheal intubation.

    After tracheal intubation

  • Fiberoptic view following the supraglottic device insertion.

    After insertion of the device

Study Arms (2)

LMA-Fastrach

ACTIVE COMPARATOR

* Induction of general anesthesia with 1,5-2,5 mg/kg propofol and 1-3 mcg/kg fentanyl and neuromuscular relaxation with 0,6 mg/kg of rocuronium. * Direct laryngoscopy, evaluation of laryngeal view grade according to Cormack-Lehane classification * Insertion of LMA-Fastrach (sizes 3,4 or 5), establishment of ventilation * Evaluation of glottic view through LMA-Fastrach using fibrescope (one out of ten patients) * Tracheal intubation through the LMA-Fastrach * With the endotracheal tube in place, the anaesthesiologist will proceed to the removal of supraglottic device

Procedure: Tracheal intubation

I-gel

ACTIVE COMPARATOR

* Induction of general anesthesia with 1,5-2,5 mg/kg propofol and 1-3 mcg/kg fentanyl and neuromuscular relaxation with 0,6 mg/kg of rocuronium. * Direct laryngoscopy, evaluation of laryngeal view grade according to Cormack-Lehane classification * Insertion of I-gel (sizes 3,4 or 5), establishment of ventilation * Evaluation of glottic view through I-gel using fibrescope (one out of ten patients) * Tracheal intubation through the I-gel * With the endotracheal tube in place, the anaesthesiologist will proceed to the removal of supraglottic device

Procedure: Tracheal intubation

Interventions

Tracheal intubation through a supraglottic airway device(LMA-Fastrach).

LMA-Fastrach

Eligibility Criteria

Age18 Years+
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • Age 18 and older
  • ASA physical status 1-3
  • Patients undergoing elective surgery under general anesthesia, requiring endotracheal intubation

You may not qualify if:

  • ASA physical status 4-5
  • Contraindications to muscle relaxation
  • Anticipated or known difficult intubation or ventilation
  • Patients with limited mouth opening (less than 2 cm)
  • Patients at increased risk of aspiration, or having an history of symptomatic gastroesophageal reflux or hiatal hernia.

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Centre Hospitalier de l'Université de Montréal-Hôpital Notre-Dame

Montreal, Quebec, H2L 4M1, Canada

Location

MeSH Terms

Interventions

Intubation, Intratracheal

Intervention Hierarchy (Ancestors)

Airway ManagementTherapeuticsIntubationInvestigative Techniques

Study Officials

  • Nathalie Massicotte, MD, FRCPC

    Centre hospitalier de l'Université de Montréal (CHUM)

    PRINCIPAL INVESTIGATOR

Study Design

Study Type
interventional
Phase
not applicable
Allocation
RANDOMIZED
Masking
NONE
Purpose
TREATMENT
Intervention Model
PARALLEL
Sponsor Type
OTHER
Responsible Party
SPONSOR

Study Record Dates

First Submitted

November 3, 2009

First Posted

November 4, 2009

Study Start

March 1, 2010

Primary Completion

May 1, 2010

Study Completion

May 1, 2010

Last Updated

August 3, 2017

Record last verified: 2017-08

Locations